SubQ Insulin | Glytec

December 11, 2019

Two Case Studies Presented at IHI National Forum Demonstrate Use of Glytec’s Technology and Services Leads to Improved Glycemic Outcomes

AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.

In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.

April 30, 2019

Metro Health – University of Michigan Health to Use Glytec’s Software for Inpatient Diabetes Care

The Wyoming, Michigan-based healthcare organization will partner with Glytec to provide patients an integrated model of technology-enabled glycemic management.

Known for high-quality, personalized care and award-winning services, Metro Health – University of Michigan Health is taking inpatient diabetes management to the next level. With a decades-long focus on ensuring glucose control is a top priority, the healthcare organization has selected Glytec’s eGlycemic Management System® (eGMS®) to advance the standardization of best practice. The software-as-a-medical-device eGMS® platform is both patented and FDA cleared.

November 8, 2018

Novant Health Goes Live With Glytec’s eGlycemic Management System®

The 14-hospital health system implements Glytec’s insulin therapy optimization solution and achieves rapid, broad-based adoption of basal-bolus best practice.

Novant Health has successfully partnered with Glytec to achieve best practice for insulin therapy in accordance with American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) guidelines. Through a combination of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) and expert clinical change management program, Novant Health of Winston-Salem, North Carolina has now transitioned from manual, paper-based protocols for sliding-scale insulin therapy to fully integrated, computer-guided decision support for basal-bolus insulin therapy.

August 29, 2018

Glytec Receives Two More Patent Allowances for its Insulin Optimization System

The newest USPTO allowances describe an integrated, connected care model for optimizing insulin therapy in the outpatient setting.

The United States Patent and Trademark Office has awarded Glytec two more patent allowances acknowledging the unique characteristics of its disruptive innovations. The allowances, which comprise a total of 52 claims, describe interactions between Glytec’s solution for insulin titration and multiple current and future-state connected diabetes technologies and health information systems, including devices, apps and other form factors for blood glucose measurement, insulin delivery and patient communication.

May 1, 2018

University of New Mexico Hospital to Bolster Patient Safety and Diabetes Care in Partnership with Glytec

New Mexico’s only academic medical center will soon implement Glytec’s evidence-based eGlycemic Management System® for best practices in insulin therapy management.

University of New Mexico Hospital, already a distinguished leader in diabetes care, is partnering with Glytec to achieve the highest levels of quality and safety for hospitalized patients who require insulin therapy. Using Glytec’s eGlycemic Management System®, the Albuquerque-based academic medical center will not only introduce greater standardization and systemization around best practices in glycemic management, but will aim to realize the very significant goal of eliminating severe hypoglycemia.

March 28, 2018

Two More Patent Allowances for Glytec’s Diabetes Software

The latest allowances from the USPTO address systems and methods specific to the dosing of subcutaneous insulin for acute and chronic care.

The United States Patent and Trademark Office (USPTO) has issued two more patent allowances for Glytec’s FDA-cleared proprietary software used by healthcare providers to guide the dosing of insulin. The allowances, which comprise a combined total of 52 claims, cite systems and methods specific to subcutaneous basal and bolus insulin. To date, Glytec has amassed an intellectual property portfolio of 18 issued or allowed patents for its eGlycemic Management System® (eGMS®) and has several dozen patents pending.

January 23, 2018

Glytec’s Software Yields Superior Patient Outcomes According to Four New Studies in Journal of Diabetes Science and Technology

Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.

Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.

December 5, 2017

Chesapeake Regional Healthcare will Implement Glytec’s Software to Bolster High-Reliability Care

Glytec’s eGlycemic Management System® will ensure clinicians have ready access to evidence-based decision support for personalized insulin therapy management.

Fostering a culture of patient safety is integral to the care Chesapeake Regional Healthcare delivers, and a new partnership with Glytec will enable best practices in glycemic management across all inpatient service lines. Glytec’s eGlycemic Management System® will support the optimization of intravenous and subcutaneous insulin therapy during hospitalization, and will provide evidence-based guidance on transitions in insulin therapy from hospital to home.

September 23, 2017

Glytec Moves Beyond Clinical Results to Touting Savings

The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.

This June, Glytec came to the American Diabetes Association (ADA) Scientific Sessions with a new story to tell. In years past, Glytec came to ADA armed with data showing that eGMS, a cloud-based glycemic management decision support system, offered a superior way for hospitals to manage insulin therapy for patients. Company officials brought a new focus to the 77th Scientific Sessions in San Diego, California, saying that it’s not enough to offer better time in range. Glytec wants to show how its results translate into what matters most to payers – and a hospital’s bottom line.

August 18, 2017

Presentation at AADE Conference Showcases Value of Diabetes Decision Support Solutions

Diabetes educators learned how Glytec’s software and other data-driven technologies help overcome key challenges of insulin management.

A presentation on diabetes decision support solutions at this year’s American Association of Diabetes Educators (AADE) conference showcased how use of Glytec’s therapy management software in conjunction with connected device systems is breaking down barriers to effective and timely insulin management and, as a result, reducing the risks and costs of diabetes for providers, payers and patients alike.

June 21, 2017

With Glytec, Hospital Moves to Basal-Bolus Insulin, Saves $9.7 Million

The move to quality ratings will put more pressure on hospitals to find ways to improve the standard of care while cutting costs.

A decade ago, the American Diabetes Association (ADA) called for hospitals to shift from sliding scale to subcutaneous basal-bolus insulin therapy for non-critically ill patients, but change has been slow in coming. Fear of hypoglycemia and concerns that staff would not be able to keep up with dosing demands of basal-bolus kept hospitals from upgrading to the standard of care.

June 20, 2017

Raymie McFarland Discusses Findings From Glytec’s Basal-Bolus Insulin Study

Glytec’s eGlycemic Management System (eGMS) helped the Kaweah Delta hospital shift its standard of care to basal-bolus insulin, explained Raymie McFarland, vice president of Quality Initiatives at Glytec. Basal-bolus is considered best practice and is safer for patients, but many hospitals have not adopted it due to its difficulty. Glytec hopes its eGMS can change that.

The poster that’s being presented is a case study looking at a 500-plus bed hospital in the San Joaquin Valley of California. It’s a facility named Kaweah Delta Regional Medical Center. Kaweah Delta is a very interesting case in that they did not have expertise from an endocrinology standpoint either in or outside the hospital or the health system facilities.

June 7, 2017

Case Studies Presented at Diabetes Technology Society Conference Highlight Millions in Hospital Cost Savings with Improved Glucose Control

One study presented at the International Hospital Diabetes Meeting observed first-year cost savings of nearly $7.5 million stemming from adoption of best practice for insulin therapy.

A series of studies and presentations included in the 6th International Hospital Diabetes Meeting highlighted the high cost of poor glucose management, and in particular, severe hypoglycemia (< 40 mg/dL) in the acute care setting. With thirty to forty percent of ALL hospitalized patients requiring insulin therapy, not just those with diabetes, the common problem of insulin mismanagement has significant impact on care quality, patient safety and patient experience, as well as cost and value.

May 8, 2017

Computer-Guided Insulin Titration Helps Hospitals Meet Basal Bolus Standard, Study Finds

An analysis of an electronic glucose management system developed by Glytec, which helps nurses safely manage basal bolus insulin dosing in the hospital, was presented at the recent meeting of the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, held in Austin, Texas.

The movement toward quality ratings — and an increased emphasis on preventing readmissions — demanded solutions that help hospitals achieve the standard, which ADA clarified in January 2017 to state that basal bolus insulin was the preferred treatment for noncritically ill patients, and that, “Prolonged sole use of sliding scale insulin in the inpatient hospital setting is strongly discouraged.”

Improving Quality of Care with Electronic Glycemic Management System

At AACE 2017, Jagdeesh Ullal, MD, MS, Eastern Virginia Medical School discussed data from his team’s study that assessed the efficacy of an electronic glycemic management system (eGlycemic Management System) in controlling blood sugars in the hospital setting.

The study was conducted at Wake Forest, but the data was collected across 9 hospitals including about 1600 patients. Ullal explained that patients with diabetes come to the hospital often have high levels of blood sugar. “In our study, the patients, on average, had blood sugar levels of 200 when they came in, and over the course of their stay, their blood sugars were brought back to the normal range (140-180). We were able to achieve that with the eGlycemic Management System software that has also been proven in various other aspects of glucose management in the hospital.”

May 4, 2017

Study Shows Computer-Guided Insulin Titration Enables Basal Bolus Standard of Care

New research presented at the AACE 26th Annual Congress further validates that use of Glytec’s eGlycemic Management System® eliminates barriers to adoption of basal bolus insulin and produces superior patient outcomes.

A multi-center post-hoc analysis presented at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific & Clinical Congress by Drs. Jagdeesh Ullal and Joseph Aloi demonstrates that Glytec’s eGlycemic Management System® (eGMS®) enables hospitals to achieve the basal bolus standard of care for subcutaneous insulin therapy with extraordinary efficiency and superior patient outcomes. The new research study, entitled ‘AUTO Study, AUtomatic Titration tO Target: Subcutaneous Basal Bolus Insulin Management Using eGMS in the Non-ICU Setting,’ observed a 19% reduction in average daily blood glucose between admission and discharge — with 0.00% severe hypoglycemia < 40 mg/dL -- while achieving the prescribed target blood glucose of 140-180 mg/dL at all mealtime and bedtime intervals.

February 16, 2017

New Research Further Validates Benefits of Personalized Diabetes Therapy Management Across the Continuum of Care

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

The 10th Annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) showcases additional evidence that use of Glytec’s patented eGlycemic Management System®, or eGMS®, leads to dramatic improvements in diabetes control and patient outcomes in both acute and outpatient settings. Two studies presented by diabetologist and researcher, Dr. Bruce Bode, find that personalized therapy management facilitated through Glytec’s eGMS® effectively reduces hemoglobin A1C, incidence of hypoglycemia and time to prescribed glucose target, all primary measures of diabetes control and patient outcomes.

February 7, 2017

Novant Health Partners with Glytec to Advance Leadership Position in Patient-Centered Diabetes Care

Glytec’s solution will enable the 14-hospital health system to achieve best practice, reduce variability and standardize care for patients with diabetes.

Becoming a national leader in diabetes care is a commitment Novant Health, headquartered in Winston-Salem, North Carolina, will advance through a new partnership with Glytec. The company’s patented eGlycemic Management System® (eGMS®) will be a focal point of the health system’s diabetes service line, offering clinicians a comprehensive set of tools, technologies and processes proven to achieve full adoption of basal-bolus insulin therapy, the standard of care and best practice endorsed by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE).

December 20, 2016

Digital Insulin Management Cuts Hospital Readmissions for CV Patients

The findings come as CMS targets cardiac procedures in both its hospital readmission reduction program and in a bundled payment model set to take effect July 1, 2017.

Glytec, which has FDA clearance for a cloud-based system to manage insulin dosing, selected MSHA as a research site for its electronic glucose management system, or eGMS. According to the studies Parsons and Mumpower presented in November at the Diabetes Technology Meeting showcase, eGMS produced sharp drops in readmission rates in 3 areas of cardiac care.

November 14, 2016

Dramatic Readmission Reductions for CABG, CHF and AMI Attributed to Glytec’s eGlycemic Management System

Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.

Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).

Page 1 of 2
1
2
→